앨나일램 파마슈티컬스 (ALNY) 주가 전망: 목표주가, 배당, 최신 뉴스

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.

It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections.

In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders.

Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers.

The company has collaborations with Regeneron Pharmaceuticals, Inc. ; Roche Holding AG; Sanofi S. A. ; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc. ; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.는 ribonucleic acid interference(RNA 간섭) 기반 치료제를 발굴·개발·제조·상용화하는 바이오기업으로 미국·유럽 등 전 세계에서 사업을 전개하고 있습니다. 본사는 Cambridge, Massachusetts에 있으며 2002년에 설립되었습니다.

주요 상용 제품으로는 ONPATTRO(유전성 트랜스티레틴 매개 hATTR 아밀로이드증), AMVUTTRA(ATTR 및 hATTR 아밀로이드증), Leqvio(고콜레스테롤혈증), Qfitlia(혈우병 A형·B형), GIVLAARI(급성 간 포르피리아), OXLUMO(원발성 고옥살산뇨증 1형) 등이 있습니다.

파이프라인은 임상 3상에 Nucresiran(ATTR 아밀로이드증), Zilebesiran(고혈압), Cemdisiran(중증근무력증·발작성 야간 혈색소뇨증·지리형 위축), Elebsiran(간염 D 바이러스 감염) 등을 포함하며, 임상 2상에는 Rapirosiran(대사성 기능 장애 관련 지방간염), ALN-ANG3(당뇨병성 신질환), ALN-4324(제2형 당뇨병), Mivelsiran(뇌 아밀로이드 혈관병증 및 알츠하이머병 관련 연구 포함), ALN-6400(출혈 질환) 등이 있습니다. 임상 1상 포트폴리오에는 ALN-2232(비만·체중관리), ALN-PNP(비알코올성 지방간질환), ALN-APOC3(이상지질혈증), ALN-CIDEB(대사성 기능 장애 관련 지방간염), ALN-HTT02(헌팅턴병), ALN-5288(알츠하이머병), ALN-SOD(SOD1 관련 ALS), ALN-SNCA(파킨슨병), AG-236(적혈구 증가증), ALN-CFB(발작성 야간 혈색소뇨증), ALN-BCAT(간세포암) 및 건강인 대상의 ALN-4285, ALN-4915, ALN-F1202 등이 포함되어 있습니다. 주요 협력사로는 Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Novartis AG, PeptiDream, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc. 등이 있습니다.

• 주소: 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142, United States

• 전화번호: 617 551 8200

• 웹사이트: https://www.alnylam.com

• 섹터: Healthcare

• 산업: Biotechnology

• 직원 수: 2,500